Zhejiang Medicine Co., Ltd. Class A

Zhejiang Medicine Co., Ltd. Class A

SSSE:600216
10.54
CNY
0.00
(0.00%)
0.46EPS
18.77P/E
11.95BMarket Cap
Apr 28Next Earn
Zhejiang Medicine Co., Ltd. Class A
SSE:600216
(Shanghai Stock Exchange)

Recent

price

10.54

P/E

ratio

18.77

div

yld

2.89%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
5.62
5.96
6.2
5.24
5.12
4.72
5.63
6.07
7.15
7.4
7.66
9.52
8.42
8.16
9.78
9.25
8.82
Revenue per Share
1.41
1.25
1
0.48
0.18
0.17
0.48
0.27
0.38
0.36
0.75
1.09
0.56
0.45
1.21
0.91
0.66
Basic EPS, GAAP
1.44
0.7
-0.16
-0.57
-0.47
-0.65
-0.05
-0.07
0.15
-0.13
0.75
0.21
-0.47
-0.17
0.56
1.5
- -
Free Cash Flow per Basic Share
0.44
0.38
0.35
0.28
0.15
0.08
0.07
0.17
0.1
0.18
1.05
0.27
0.36
0.2
0.18
0.39
0.3
Dividend per Share
4.76
5.42
6.61
6.9
6.98
7.05
7.25
7.55
7.92
8.14
7.95
9.1
9.59
9.98
11.07
11.38
11.95
Book Value per Share
4.71
5.33
6.39
6.54
6.61
6.61
6.79
7.12
7.49
7.72
7.53
8.3
8.79
9.19
10.36
10.75
11.3
Tangible Book Value per Share
811
810
849
942
943
952
938
938
959
952
957
959
964
955
959
960
956
Basic Weighted Avg Shares
4,558
4,826
5,264
4,933
4,832
4,497
5,279
5,693
6,859
7,044
7,327
9,129
8,116
7,794
9,375
8,881
8,431
Sales/Revenue/Turnover
31.28
25.77
18.98
11.69
6.41
1.1
13.05
6.61
8.84
6.03
12.85
14.77
8.16
1.99
16.09
12.15
10.1
Operating Margin (%)
134
148
159
167
266
295
339
376
429
488
504
588
682
725
723
794
- -
Depreciation Expense
1,145
1,012
849
452
170
162
450
253
365
343
717
1,045
540
430
1,161
873
633
Net Income, GAAP
14.22
14.49
14.51
17.35
18.44
17.96
17.76
20.3
26.2
26.55
22.48
23.32
26.21
23.81
15.84
20.12
22.29
Effective Tax Rate (%)
25.11
20.98
16.12
9.16
3.51
3.6
8.53
4.45
5.32
4.87
9.79
11.45
6.65
5.51
12.38
9.83
7.51
Profit Margin (%)
2,183
2,697
3,635
2,810
2,192
1,892
2,253
2,696
3,002
2,989
3,194
3,010
3,190
3,123
4,015
4,771
5,697
Working Capital
- -
- -
- -
- -
- -
20
135
120
12
- -
501
251
201
231
171
358
476
LT Debt
3,863
4,400
6,197
6,480
6,562
6,615
6,992
7,779
8,084
8,252
8,030
9,182
9,710
9,986
10,868
11,089
11,879
Total Equity
32.43
24.29
16.16
7.22
3.38
2.16
6.27
3.38
4.1
3.43
7.57
9.31
3.57
2.71
9.08
6.44
- -
Return on Invested Capital (%)
32.96
24.42
15.54
6.99
2.61
2.7
6.53
3.6
4.98
4.72
9.07
12.99
7.2
5.67
11.81
8.54
- -
Return on Capital (%)
34.14
24.55
16.04
7.15
2.61
2.46
6.63
3.55
4.88
4.42
9.24
12.71
5.98
4.55
11.45
8.09
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
453
307
456
LT Borrowings
504
604
475
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
962
962
962
Market Capitalization
15,454
10,963
11,953

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
7,153
7,996
7,897
Cash, Cash Equivalents & STI
3,240
4,004
3,767
Accounts Receivable, Net
1,592
1,519
1,489
Inventories
1,797
2,046
2,180
Total Current Liabilities
2,111
1,948
2,199
Payables & Accruals
- -
- -
- -
ST Debt
453
307
456
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.41%
6.76%
2.03%
Free Cash Flow
-194.61%
-145.44%
169.45%
Net Income, GAAP
40.41%
24.47%
-24.74%
Sales/Revenue/Turnover
7.7%
4.91%
-5.28%
Total Cash Common Dividend
68.19%
5.09%
121.19%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,249
2,156
2,707
2,262
9,375
2025
2,255
2,067
- -
2,185
8,881
2026
2,191
2,195
1,860
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.21
0.56
0.32
1.21
2025
0.43
0.28
- -
-0.06
0.91
2026
0.3
0.34
0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.16
- -
0.18
2025
0.01
0.01
- -
0.01
0.39
2026
- -
0.01
0.29
- -
- -
Business
Zhejiang Medicine Co., Ltd. (600216.SS) manufactures and markets life nutrition products, pharmaceuticals, and active pharmaceutical ingredients primarily in China with global sales reach. The company produces synthetic vitamin E, natural vitamin E, vitamin A, vitamin D3, vitamin H (biotin), coenzyme Q10, beta-carotene, canthaxanthin, lutein, lycopene; pharmaceutical raw materials including anti-resistant antibiotics, antimalarial drugs, quinolones, hypoglycemic agents, hormones; finished dosage forms such as injectable levofloxacin lactate, vancomycin hydrochloride injections, teicoplanin; animal nutrition additives; human nutrition products; and aroma ingredients. Founded in 1997 through the merger of several pharmaceutical entities and headquartered in Shaoxing, Zhejiang Province, China, Zhejiang Medicine focuses on fat-soluble vitamins, carotenoids, antibiotics, and nutraceuticals for pharmaceutical, food, feed, and personal care industries, serving domestic and international markets across Asia, Europe, North America, and beyond. In a significant recent development announced in late 2025, the company plans to spin off its antibody-drug conjugate (ADC) subsidiary Novocodex for a separate listing on the Hong Kong Stock Exchange to optimize capital allocation and advance its ADC pipeline, including assets like HER2-targeting NCB001 and ARX788; Novocodex previously raised RMB 400 million in Series B funding in 2022.